Compare JZXN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JZXN | INDP |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 4.0M |
| IPO Year | 2021 | N/A |
| Metric | JZXN | INDP |
|---|---|---|
| Price | $2.35 | $2.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 650.1K | 41.8K |
| Earning Date | 03-05-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,465.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.12 | $1.65 |
| 52 Week High | $312.80 | $47.60 |
| Indicator | JZXN | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 42.80 |
| Support Level | $2.12 | $2.39 |
| Resistance Level | $2.78 | $2.94 |
| Average True Range (ATR) | 0.76 | 0.23 |
| MACD | 0.27 | 0.04 |
| Stochastic Oscillator | 26.63 | 27.85 |
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.